Guide
Biotech scale-up gaps that blow timelines
Science rarely fails first. Interfaces do — materials vs process, QC vs campaign cadence, capacity vs cash. Here is how emerging teams mis-sequence scale-up, and what to decide this quarter.
The pattern
Emerging biotechs push titer, assays, and clinical supply while the operating system — materials planning, release cycle time, suite ownership, deviation load — lags. The first painful signal is usually a slipped lot or a surprise CapEx ask, not a failed experiment.
Four gaps that compound
- Materials vs process intent — specs and lead times that worked at pilot collapse when dual campaigns or tox demand hit.
- Release as the silent bottleneck — USP/DSP capacity looks fine until QC queue time eats the calendar.
- Capacity without matching people — steel installed faster than trained operators and clear ownership.
- Decision debt — no ranked Now/Next/Later, so every fire feels equally urgent.
What to freeze this quarter
Pick the interface most likely to blow the next milestone. Document ownership. Sequence the rest. That is the job of a focused Operational Scale-Up Assessment — a working decision tool customized to your situation, not a generic maturity checklist or only a PDF.
Try the free Scale-Up Readiness scorecard, play Line Balance Lab, or open the COGS preview— those magnets are live. Then check fit for the $4,500 first pass. A full customer portal to maintain the tool is not shipped on this site yet.